Katja Rosenkranz

Katja Rosenkranz is a Partner at V-Bio Ventures. Prior to joining V-Bio Ventures, Ms. Rosenkranz served as senior investment and project manager at ascenion gmbh from January 2011 to January 2016. Ms. Rosenkranz also served as CBO and chief financial officer at Hepa Wash GmbH from January 2007 to January 2011. Additionally, Ms. Rosenkranz has served as interim chief executive officer agomab therapeutics since February 2018 and as managing director of Dr. Katja Rosenkranz & Rainer Friedl GBR since January 2007. Ms. Rosenkranz began their career as an investment analyst and associate at Polytechnos Venture-Partners from January 2003 to January 2007. Ms. Rosenkranz holds a Ph.D from the Max Planck Institute of Neurobiology, which they obtained in January 1998.

Katja Rosenkranz has a master of business administration from the University Witten / Herdecke and a doctorate in philosophy from the University Witten/Herdecke & MPI Neurobiology in Munich.

They work with Martin Solleveld - Finance Manager, Ethan Kuo - Analyst, and Charles Margarit - Analyst. Katja Rosenkranz reports to Christina Takke, Managing Partner.